ArticleWorld journal of surgical oncology2026
Prognostic impact of epidermal growth factor receptor mutation in grade 3 stage IA lung adenocarcinomas.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesStage IA adenocarcinomas (LUAD) with high-risk features exhibited an increased recurrence rate, and the role of adjuvant therapy in this population remains controversial. Our study aimed to evaluate the prognostic impact of epidermal growth factor receptor (EGFR) mutation in grade 3 stage IA LUAD.
methodsBetween 2016 and 2020, 483 consecutive patients undergoing operation, with grade 3 pathologic stage IA LUAD were evaluated. The Kaplan-Meier analysis was performed to assess recurrence-free survival (RFS) and overall survival (OS). Prognostic factors were evaluated using the Cox proportional hazards model.
resultsAn EGFR mutation was identified in 238 patients (49.3%), including 122 (51.3%) with an exon 19 deletion (Ex 19), 100 (42.0%) with an exon 21 L858R (Ex 21), and 16 (6.7%) with other EGFR mutations. The adjuvant chemotherapy was performed in 23 (4.8%) cases. EGFR mutant showed worse RFS than EGFR wild type (5-year RFS, 88.8% vs. 94.4%, p = 0.016). Subgroup analysis stratified by tumor size indicated that, among patients with pT1c tumors, EGFR mutant had a statistically lower 5-year RFS compared with EGFR wild type (n = 117; 83.1% vs. 96.2%; p = 0.036). Multivariable Cox regression analysis revealed that perineural invasion and EGFR mutation (HR = 2.095, 95%CI, 1.118 to 3.924) were independent predictors of worse RFS.
conclusionsIn grade 3 stage IA3 LUAD, the presence of an EGFR mutation was associated with a poorer prognosis compared with EGFR wild type. These findings underscore the potential need to explore tailored adjuvant treatment strategies in this subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.